Business
Shuttle Pharmaceuticals Awarded New HDAC Inhibitor Patents for Cancer Treatment
Company awarded patents in the U.S. and Hong Kong ROCKVILLE, Md., Sept. 15, 2022 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a
About this update from Shuttle Pharmaceuticals Holdings, Inc.
[{"type":"text","content":"Company awarded patents in the U.S. and Hong Kong \nROCKVILLE, Md., Sept. 15, 2022 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company, announced today that it has been awarded patents in the U.S. and Hong Kong for its radiation sensitizing HDAC inhibitor technology platform, which is focused on reducing side effects and improving outcomes for cancer patients treated with radiation therapy (RT).\n\n \n \n \n \n \n \n\n \n\"We are pleased to have been awarded these additional U.S. and Hong Kong patents,\" said Dr. Anatoly Dritschilo, Chief Executive Officer of Shuttle Pharmaceuticals. \"We are developing our platform with the goal of being on the leading-edge in helping cancer patients treated with radiation therapy have the best possible outcomes and dramatically improve their quality of life.\"\n\"We are building a robust portfolio of drug candidates to sensitize cancer to radiation therapy and to activate the immune system to target irradiated tumor cells,\" continued Dr. Dritschilo. \"Selective HDAC6 inhibitors are an emerging class of pharmaceuticals with significant applications in cancers, neurodegenerative diseases and immunology.\"\nVarious sources have estimated that more than 800,000 patients in the US are treated with radiation therapy for their cancers. According to the American Cancer Society about 50% are treated for curative purposes and the balance for therapeutic care. The market opportunity for radiation sensitizers lies with the 400,000 patients treated for curative purposes. The number of patients being treated with RT is expected to grow by more than 22% over the next five years. Based on a rough estimate of a course of radiation sensitizing brand drug therapy (used off label at this time) of $12,000 per patient—the market size would be in excess of $4.0 billion annually.\nHistone deacetylase (HDAC) inhibitors have been described as \"a novel class of drugs that target enzymes involved in regulation of critical cellular functions that can inhibit cancer growth and activate cellular immunity,\" according to Scott Grindrod, PhD, lead inventor and Laboratory Director at Shuttle Pharmaceuticals.\nTreatment with HDAC inhibitors allows regulation of gene expression by blocking HDAC enzyme activity and allowing genes to be \"turne...